21:56 , Jan 5, 2017 |  BC Week In Review  |  Clinical News

ATI-50001: Ph I started

Aclaris began a Phase I trial to evaluate oral ATI-50001 in 12 healthy volunteers. Aclaris has exclusive, worldwide rights to ATI-50001 from Rigel under a 2015 deal (see BioCentury, Sept. 14, 2015 ). Aclaris Therapeutics...
01:05 , May 28, 2016 |  BC Extra  |  Financial News

Aclaris raises $20M in private placement

Aclaris Therapeutics Inc. (NASDAQ:ACRS) raised $20 million through the sale of 1.1 million shares at $18.50 in a private placement led by new investor Aisling Capital . Undisclosed new and existing investors also participated. William...